Employees: 2,691
Size Jiangsu Hanvo Safety Product (300952.SZ) is a China Health Care company (Medical Specialties) with a market value of $575M, the 3353rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.42 on 18 Nov 2026.
Performance Over six months the shares fell 38.2%, against +3.2% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 19 in its peer set.
Growth Revenue grew 6.5% over the last twelve months (peer median +14.4%); the operating margin is 7.5% (peer median 6.5%).
Valuation It trades at 39.7× forward earnings against a peer median of 23.5× (3rd most expensive of 10).
Capital Return on invested capital runs 1.3 points below its cost of capital (7.2% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.35B | CN¥1.22B | CN¥1.27B | CN¥967M | CN¥889M |
| Revenue growth | — | -3% | +31% | +9% | — |
| Gross profit | CN¥400M | CN¥275M | CN¥265M | CN¥225M | CN¥210M |
| EBITDA | n/a | CN¥234M | CN¥201M | CN¥176M | CN¥153M |
| Net income | CN¥70.1M | CN¥102M | CN¥117M | CN¥106M | CN¥122M |
| Free cash flow | -CN¥178M | -CN¥381M | -CN¥229M | -CN¥113M | -CN¥128M |
| Capital expenditure | CN¥389M | CN¥580M | CN¥332M | CN¥216M | CN¥318M |
| Total debt | CN¥774M | CN¥579M | CN¥736M | CN¥285M | CN¥110M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300952.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.0% | -1.9% | 8th highest of 19 |
| 6-month return | -38.2% | +3.2% | 2nd lowest of 19 |
| Distance from 52-week high | -59.0% | -31.6% | 3rd lowest of 20 |
| Revenue growth (TTM) | +6.5% | +14.4% | 10th lowest of 20 |
| Operating margin | 7.5% | 6.5% | 9th highest of 20 |
| Forward P/E | 39.7× | 23.5× | 3rd most expensive of 10 |
| ROIC minus cost of capital | -1.3 pp | -5.4 pp | 9th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 39.7× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | n/a | n/a | n/a |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 33.7× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | n/a | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | n/a | n/a | n/a |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 12.0× | n/a | n/a |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 18.9× | 0.4% | +27.8% |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 21.1× | 8.4% | +12.0% |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | n/a | n/a | n/a |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 31.8× | -1.2% | +14.5% |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 98.6× | 35.3% | +6.7% |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | n/a | 15.0% | -19.8% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 23.5× | 10.2% | +6.5% |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 53.1× | 35.9% | +35.2% |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $618M | -27% | -13% | 31% | 17.4× | -8.5% | +2.2% |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | n/a | n/a | n/a |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | n/a | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $630M | 0% | +19% | 51% | n/a | -2.6% | +18.8% |